Advertisement

Topics

AI firm Insitro signs Gilead as first pharma partner with NASH deal

05:23 EDT 17 Apr 2019 | pharmaphorum

Less than a year after coming out of stealth mode with a $65 million first-round last year, artificial intelligence specialist Insitro has already signed its first biopharma partner. The South San Francisco company has enticed Gilead with its visi...

Original Article: AI firm Insitro signs Gilead as first pharma partner with NASH deal

NEXT ARTICLE

More From BioPortfolio on "AI firm Insitro signs Gilead as first pharma partner with NASH deal"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...